Safety assessment and sub-group analysis (gender-based and age-based) of Rocuronium: A real-world pharmacovigilance study from the FAERS database.

BACKGROUND Most of the evidence for rocuronium-related adverse events came from clinical trials or case reports, with relatively small sample sizes. It is currently unclear whether rocuronium may cause other serious adverse reactions. This study aims to analysis adverse events related to rocuronium from FAERS database. METHODS The adverse events data related to rocuronium from 2004 Q1 to 2024 Q2 were collected. After standardizing the data, signal quantification techniques (ROR, PRR, BCPNN and EBGM) were used for analysis. Gender-based and age-based differences were also conducted. RESULTS Among the 3316 adverse event reports with rocuronium as the primary suspected drug, 191 preferred terms of adverse reactions spanning 23 different system organ classes were identified. Anaphylaxis, residual paralysis, myopathy and increased pulmonary vascular resistance were common adverse events of rocuronium. Some unexpected adverse reactions were also founded, such as acquired dysfibrinogenaemia, postresuscitation encephalopathy, hypersensitivity myocarditis, hyperthermia malignant and cardiac arrest. Gender-based differences were found, especially in Respiratory, thoracic and mediastinal disorders, Cardiac disorders, Nervous disorders, Musculoskeletal and connective tissue disorders, etc. And more life-threatening adverse reactions, such as cardiac failure acute and acute pulmonary oedema, were found in elderly patients. Anaphylactic shock, anaphylactic reaction and cardiac arrest were the three leading causes of death related to rocuronium. CONCLUSIONS These findings advise medical professionals to exercise more caution when using rocuronium, especially in elderly people. This study provide guidance for early identification of rocuronium-related adverse reactions, and valuable references for more in-depth future studies and safety regulatory work.

• Publication year

  2025

• Venue

  European Journal of Pharmacology

• Publication date

  2025-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2025.178351PMID 41207356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Japanese Epidemiologic Study for Perioperative Anaphylaxis, a prospective nationwide study: allergen exposure, epidemiology, and diagnosis of anaphylaxis during general anaesthesia.

  2023cited by this paper
• Neuromuscular Blockade in the Pre- and COVID-19 ARDS Patients

  2022cited by this paper
• Suicide committed by a paramedic using a cocktail of drugs: Morphine, etomidate, diazepam and rocuronium. Case report and review of literature.

  2021cited by this paper
• Risk of post-intubation cardiac arrest with the use of high-dose rocuronium in COVID-19 patients with acute respiratory distress syndrome: A retrospective cohort study

  2021cited by this paper
• Onset time and duration of action of rocuronium 0.6 mg/kg in patients above 80 years of age: A comparison with young adults

  2020cited by this paper
• Life-threatening rocuronium-induced anaphylactic shock without cutaneous manifestations successfully reversed with sugammadex: a case report

  2020cited by this paper
• Two Cases of Rocuronium-Induced Anaphylaxis/Anaphylactic Shock Successfully Treated With Sugammadex.

  2019cited by this paper
• Focus on the agents most frequently responsible for perioperative anaphylaxis

  2018cited by this paper
• [A Case of Rocuronium-induced Anaphylaxis in a Man with Kounis Syndrome in which Basophil Activation Test was Valuable in Determining the Causative Agent].

  2017cited by this paper
• Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications

  2015cited by this paper
• Successful anesthesia in a patient with a history of cardiac arrest following rocuronium injection

  2014cited by this paper
• Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis.

  2014cited by this paper
• Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents.

  2013cited by this paper
• Rocuronium and malignant hyperthermia.

  2012cited by this paper
• Delayed-onset malignant hyperthermia in association with rocuronium use.

  2012cited by this paper
• Sudden death of a young ICU doctor by injection with the muscle relaxant, rocuronium bromide. Committed suicide or sound alike medication error?

  2009cited by this paper
• Influence of gender on the course of neuromuscular block following a single bolus dose of cisatracurium or rocuronium

  2008cited by this paper
• Malignant Hyperthermia

  2005cited by this paper
• [Suicide by intravenous injection of rocuronium-bromide--case report].

  2005cited by this paper
• The Risk of Anaphylactic Reactions to Rocuronium in the United States Is Comparable to That of Vecuronium: An Analysis of Food and Drug Administration Reporting of Adverse Events

  2005cited by this paper
• Masseter spasm after pancuronium.

  1980cited by this paper

• No citing papers are available for this paper.